MARKET

ACAD

ACAD

ACADIA Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.60
+0.17
+0.83%
After Hours: 20.63 +0.03 +0.15% 18:47 04/13 EDT
OPEN
20.50
PREV CLOSE
20.43
HIGH
20.90
LOW
20.42
VOLUME
1.75M
TURNOVER
--
52 WEEK HIGH
58.72
52 WEEK LOW
20.12
MARKET CAP
3.30B
P/E (TTM)
-11.5065
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12)
Benzinga · 16h ago
Acadia Pharmaceuticals Cannot Catch a Break With Quant Downgrade
Acadia Pharmaceuticals (ACAD) Cannot Catch a Break With Quant Downgrade...ACAD
TheStreet.com · 1d ago
The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of defensives such as healthcare stocks.
Benzinga · 3d ago
Estrogen Receptor Beta Market Latest Research On Industry Growth, Trends, Top Players, & Key Regions By 2027
Apr 08, 2021 (Market Insight Reports) -- The latest report as Estrogen Receptor Beta Market acknowledges Size, Application Segment, Type, Regional Outlook,...
Market Insight Reports · 5d ago
Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates
The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.
Zacks · 6d ago
Fibrogen hurt by downgrades, Emergent earns a bull despite vaccine mix-up and more in today’s analyst action
Today pre-market analyst action includes downgrades on Fibrogen and ACADIA due to recent FDA decisions on companies’ new drug applications.Fibrogen slips as analysts weigh in on safety updateFibrogen (FGEN) shares
Seekingalpha · 6d ago
The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 6)
Benzinga · 6d ago
DJ ACADIA Pharmaceuticals Price Target Cut to $18.00/Share From $43.00 by HC Wainwright & Co.
Dow Jones · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACAD. Analyze the recent business situations of ACADIA Pharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 20 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACAD stock price target is 29.44 with a high estimate of 70.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 468
Institutional Holdings: 161.76M
% Owned: 101.07%
Shares Outstanding: 160.05M
TypeInstitutionsShares
Increased
93
5.57M
New
72
5.06M
Decreased
97
10.85M
Sold Out
30
1.57M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.86%
Pharmaceuticals & Medical Research
+0.68%
Key Executives
Chairman/Independent Director
Stephen Biggar
President
Srdjan Stankovic
Chief Executive Officer/Director
Stephen Davis
Chief Financial Officer/Executive Vice President
Elena Ridloff
Executive Vice President/General Counsel/Secretary
Austin Kim
Executive Vice President
Gudarz Davar
Senior Vice President/Chief Marketing Officer
Charmaine Lykins
Senior Vice President
Stephanie Fagan
Senior Vice President
Amanda Morgan
Vice President/IR Contact Officer
Mark Johnson
Senior Vice President
Mark Schneyer
Senior Vice President
Ponni Subbiah
Chief Accounting Officer
James Kihara
Director
Elizabeth Garofalo
Independent Director
Julian Baker
Independent Director
Laura Brege
Independent Director
James Daly
Independent Director
Edmund Harrigan
Independent Director
Daniel Soland
No Data
  • All
  • Financials
  • Insiders
More
About ACAD
ACADIA Pharmaceuticals Inc. (ACADIA) is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines to address the medical needs in central nervous system disorders. The Company's lead product, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA’s developments are focused on pimavanserin for additional neuropsychiatric conditions, trofinetide for Rett syndrome, ACP-044 for pain management and an early-stage muscarinic receptor program.

Webull offers kinds of ACADIA Pharmaceuticals Inc. stock information, including NASDAQ:ACAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACAD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACAD stock methods without spending real money on the virtual paper trading platform.